Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine

Stock Markets May 11, 2022 15:11
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus Veru Suggested By FDA To Submit Emergency Use Request For Sabizabulin In COVID-19 In a Pre-EUA meeting, the FDA said Veru Inc (NASDAQ: VERU) should submit a request for FDA emergency use authorization (EUA) for sabizabulin in hospitalized COVID-19 patients.

The FDA agreed that the Phase 3 COVID-19 study stopped by the Independent Data Monitoring Committee for overwhelming efficacy is sufficient to support the efficacy portion of a request for EUA submission and marketing application submission.

The FDA also agreed that the current safety data available for sabizabulin is sufficient to support the safety portion of a request for EUA submission.

Shares are up 24.3% at $9.68 during the premarket session.

Eli Lilly (NYSE:LLY)'s Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19 The FDA approved Eli Lilly And Co 's (NYSE: LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Olumiant remains under EUA status for hospitalized pediatric patients between the ages of two and 18 years-old requiring supplemental oxygen, mechanical ventilation, or ECMO.

Click here to access Benzinga's FDA Calendar

Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV Sanofi (EPA:SASY) SA (NASDAQ: SNY) and AstraZeneca plc's (NASDAQ: NASDAQ:AZN) prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV) demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% against medically attended lower respiratory tract infections due to RSV in infants.

In a separate pooled post-hoc analysis, nirsevimab exhibited RSV neutralizing antibodies approximately 50-fold higher than baseline at Day 151 post-dose.

Bioasis, Neuramedy Ink Licensing Pact For Neurology-Focused Candidate Bioasis Technologies Inc (OTC: BIOAF) has entered into a research collaboration, and license agreement with Korea-based Neuramedy Co Ltd focused on disease-modifying treatments for Parkinson's disease and other synuclein-related diseases.

Under the agreement terms, Neuramedy has obtained worldwide rights to research, develop and commercialize an XB3TM version of its antibody, Tomaralimab, currently in development for Parkinson's and Multiple System Atrophy.

Bioasis will receive an upfront payment and may receive an additional $72 million in milestone payments and a royalty on net sales.

Genentech's Tiragolumab/Tecentriq Fails On Progression-Free Survival In PD-L1-High Metastatic Lung Cancer Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).

The trial evaluated tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment in 534 NSCLC patients.

The study did not meet its co-primary endpoint of progression-free survival.

At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis.

Arcellx Starts Dosing In Multiple Myeloma CAR-T cell Therapy Trial Arcellx Inc (NASDAQ: ACLX) has dosed the first patient in its open-label, multicenter ACLX-001 Phase 1 trial of its novel ARC-SparX program in patients with relapsed or refractory multiple myeloma.

ARC-SparX is a universal cell therapy platform comprised of SparX (soluble protein antigen-receptor X-linkers) proteins engineered to target BCMA on myeloma cells and Antigen Receptor Complex cells dosed separately.

Initial data from the ACLX-001 Phase 1 study is expected in 2023.

NexImmune, Yale, JDRF Ink Research Pact For Type 1 Diabetes NexImmune Inc (NASDAQ: NEXI), Yale, and JDRF have begun a two-year project exploring NexImmune's AIM nanoparticles combined with a murine surrogate of teplizumab against diabetes antigen-specific T cells.

The $600,000 grant, funded by JDRF to Yale, is a part of its Cures research portfolio, which includes therapies to prevent type 1 diabetes.

FDA Extends Review Period For Amicus's Pompe Disease Candidate Application The FDA has extended the review period by 90 days for Amicus Therapeutics Inc's (NASDAQ: FOLD) marketing applications of cipaglucosidase alfa and miglustat, the two components of AT-GAA.

The revised PDUFA action dates for miglustat and cipaglucosidase alfa are Aug. 29 and Oct. 29, respectively.

The FDA extended the PDUFA dates to allow additional time to review the information submitted by Amicus as part of its ongoing reviews.

The extension of the review timeline was not related to requests for any additional clinical data.

Inovio Announces CEO Transition Inovio Pharmaceuticals Inc (NASDAQ: INO) appointed Jacqueline Shea as President and Chief Executive Officer, effective immediately.

Dr. Shea succeeds Dr. Joseph Kim.

Shea joined the company in March 2019 as Chief Operating Officer.

INO shares closed 18.9% lower at $2.02 during after-hours trading.

Eiger, AnGes Ink Exclusive Partnership for Regulatory Approval, Commercialization Of Lonafarnib In Japan Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) and AnGes Inc have entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy (lonafarnib) for progeria (premature aging in children) and processing-deficient progeroid laminopathies in Japan.

Under the agreement terms, AnGes is responsible for obtaining and maintaining regulatory approval for Zokinvy in Japan and will be the exclusive partner for distribution and commercialization.

Eiger will receive upfront and milestone payments up to $1.5 million and earn revenue from the sale of Zokinvy to AnGes.

Offerings Exicure Inc (NASDAQ: XCUR) has agreed to sell 26.02 million shares at $0.1937 per share in a private placement in public equity financing for gross proceeds of approximately $5 million.

Shares were trading 35.09% higher at $0.14 on Wednesday morning, according to Benzinga Pro.

Earnings Trevena Inc (NASDAQ: TRVN): Before the market open.

Pieris Pharmaceuticals Inc (NASDAQ: PIRS): Before the market open.

PDS Biotechnology Corp (NASDAQ: PDSB): Before the market open.

Xeris Biopharma Holdings Inc (NASDAQ: XERS): Before the market open.

Evotec SE (NASDAQ: EVO): Before the market open.

Genmab A/S (NASDAQ: GMAB): During market trading.

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC): After market close.

TFF Pharmaceuticals Inc (NASDAQ: TFFP): After market close.

BioCardia Inc (NASDAQ: BCDA): After market close.

TRACON Pharmaceuticals Inc (NASDAQ: TCON): After market close.

© 2022 Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
Sign up with Email